Skip to content

Ingestion of probiotics (a Lactobacillus rhamnosus formula) as complementary therapy in the treatment of patients with plaque psoriasis (an inflammatory disease of the skin)

Use of a Lactobacillus rhamnosus formula as adjuvant in the treatment of plaque psoriasis patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-8js7t83
Enrollment
Unknown
Registered
2022-08-02
Start date
2021-05-20
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

All included subjects were 18 years old or older, had plaque psoriasis, were not pregnant and did not have other skin diseases, neoplasms nor systemic inflammatory diseases (such as Crohn’s disease, i
G07.203.300.456.500

Sponsors

Enrico Stefano Suriano
Lead Sponsor
Faculdade de Ciências Médicas da Santa Casa de São Paulo
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Being over 18 years old; having plaque psoriasis.

Exclusion criteria

Exclusion criteria: Being pregnant; having other skin diseases, neoplasms or systemic inflammatory diseases (such as Crohn’s disease, inflammatory bowel disease, vasculitis and sarcoidosis).

Design outcomes

Primary

MeasureTime frame
Changes in mean PASI (Psoriasis Area of Severity Index). In the beginning of the study, we expected to find a difference of 30% between groups after 6 months of administration of probiotics. After the study was completed, the observed difference was of 20% (reduction of mean PASI of 3.06 in the experimental group and of 2.46 in the control group, with p=0.62).

Countries

Brazil

Contacts

Public ContactEnrico Suriano

Faculdade de Ciências Médicas da Santa Casa de São Paulo

enrico.suriano@aluno.fcmsantacasasp.edu.br+55 (11) 3367-7883

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 12, 2026